$23.040
+0.574 (+2.49%)收盘时
LTGO 同业对比
In the context of the broader market, LTGO competes directly with industry leaders such as PAHC and AVLN. With a market capitalization of $1.45B, it holds a significant position in the sector. When comparing efficiency, LTGO's gross margin of N/A stands against PAHC's 31.73% and AVLN's N/A. Such benchmarking helps identify whether Latigo Biotherapeutics, Inc. is trading at a premium or discount relative to its financial performance.
LTGO 财务表现
The company shows a P/E ratio of -36.00 and a forward P/E of 0, suggesting it is not generating profits currently. Additionally, the price-to-sales ratio is 0, indicating no revenue generation, and the price-to-free cash flow ratio is -32.71, highlighting cash flow issues.
Financials
本页仅供研究参考，不构成投资建议。模型可能出错。过往表现不代表未来结果。